Science Explorer Back to mapMap
Discussion
Researcher · Mid Yorkshire Hospitals NHS Trust · United Kingdom

John Ashcroft

John Ashcroft publishes mostly in Hematology, Oncology and Infectious Diseases, on topics such as Multiple Myeloma Research and Treatments, Bone health and treatments and Cancer Treatment and Pharmacology.

ORCID 0000-0002-9252-4180 OpenAlex
World rank
#715,566
of 7,710,434 ranked researchers
Rank in United Kingdom
#60,161
of 367,258
Works
122
Citations
4.4k
Citations per work
35.7
h-index
24
i10-index 38Top 18% in Hematology
John Ashcroft

What does John Ashcroft research?

John Ashcroft's work is mostly in Medicine (57%), Biochemistry, Genetics and Molecular Biology (7%).

Health Sciences: 70 works · 57.2% of their workMedicine: 70 works · 57.2% of their workHematology: 25 works · 20.5% of their workOncology: 25 works · 20.5% of their workInfectious Diseases: 9 works · 7.2% of their workGenetics: 6 works · 4.7% of their workSurgery: 5 works · 4.3% of their workEverything else: 44 works · 36.3% of their workLife Sciences: 8 works · 6.5% of their workBiochemistry, Genetics and Molecular Biology: 8 works · 6.5% of their workMolecular Biology: 8 works · 6.5% of their workTHEIR WORKJohn Ashcroft122works
Life Sciences7%Health Sciences57%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine7057.2%
  2. Everything else4436.3%
    1. Biochemistry, Genetics and Molecular Biology86.5%
  1. 1Hematology20% of their works
  2. 2Oncology20% of their works
  3. 3Infectious Diseases7% of their works
  4. 4Molecular Biology6% of their works
  5. 5Genetics5% of their works
  6. 6Surgery4% of their works

Research topics

Which keywords describe John Ashcroft's research?

The keywords of their largest research topics: Diagnosis Criteria, International Myeloma Working Group, Bisphosphonates, Osteonecrosis of the Jaw, Chemotherapy-Induced Peripheral Neuropathy, Prognostic Factors, Taxanes and BET Bromodomains.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 17 words, with their numbers
  1. Diagnosis Criteria471 topic
  2. International Myeloma Working Group471 topic
  3. Bisphosphonates211 topic
  4. Osteonecrosis of the Jaw211 topic
  5. Chemotherapy-Induced Peripheral Neuropathy141 topic
  6. Prognostic Factors142 topics
  7. Taxanes141 topic
  8. BET Bromodomains121 topic
  9. PROTACs121 topic
  10. Clinical Characteristics91 topic
  11. SARS-CoV-291 topic
  12. Metastatic Spine Tumors81 topic
  13. Spinal Metastases81 topic
  14. Chronic Lymphocytic Leukemia61 topic
  15. Fibroblast Activation Protein61 topic
  16. Genomic Aberrations61 topic
  17. Tumor Microenvironment61 topic

Where does John Ashcroft work?

John Ashcroft's main affiliation in the publication record is Mid Yorkshire Hospitals NHS Trust, United Kingdom.

How many publications and citations does John Ashcroft have?

OpenAlex counts 122 works and 4,356 citations for John Ashcroft, an h-index of 24, ranking #715,566 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Other researchers named John Ashcroft

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about John Ashcroft. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.